GLP-1 Medicines After Bariatric Surgery: What the Trials Show About Weight Regain and Low Dose Use

Can GLP-1 medicines help with weight regain after bariatric surgery? The research says yes, on average by a meaningful amount. One randomized trial and several meta-analyses show that liraglutide, semaglutide and tirzepatide produce additional weight loss in people whose weight crept back, or never fell far enough, after a sleeve gastrectomy or gastric bypass.

The question comes up a lot. A 2025 meta-analysis in Obesity Surgery estimated that 15 to 40% of patients experience recurrent weight gain after metabolic bariatric surgery. Surgery remains the most powerful single treatment for severe obesity, but for a sizeable minority the result fades, and the next step used to be diet counselling or another operation.

This article covers what the trials found, how the drugs compare, how a GLP-1 stacks up against revision surgery, which safety problems are specific to a rearranged gut, and what is known (very little) about lower or microdose regimens in this group.

Why does weight come back after bariatric surgery?

Regain and suboptimal response

Weight comes back after bariatric surgery for several overlapping reasons, and gut hormones are one of them. Part of the effect of a sleeve or bypass is hormonal: after surgery, food reaches the lower gut faster and the body releases more of its own GLP-1, which helps curb appetite. The BARI-OPTIMISE investigators note that poor weight loss after surgery is associated with lower circulating levels of GLP-1.

Researchers now separate two patterns. A suboptimal initial clinical response means the weight never fell as far as expected. Recurrent weight gain means it fell, then rose again. A 2026 study from Hospital Clínico San Carlos in Madrid cited roughly 30% of patients experiencing recurrent weight gain within 2 years of surgery, and the patients in that study had regained an average of 23.6% from their lowest weight.

The hormonal link is the reason a GLP-1 medicine makes intuitive sense here: it supplies, in drug form, a signal that may have weakened. Whether that reasoning holds up is a question the trials have started to answer.

Do GLP-1 medicines work for weight regain after bariatric surgery?

The BARI-OPTIMISE randomized trial

Yes, in the one placebo-controlled weight trial that exists. BARI-OPTIMISE, published by Mok and colleagues in JAMA Surgery in 2023, enrolled 70 adults at least 1 year after a sleeve gastrectomy or gastric bypass who had lost 20% or less of their body weight and had a weak GLP-1 response to a test meal. Their mean age was 47.6, and 74% were women.

Participants took liraglutide 3.0 mg once daily or placebo for 24 weeks, both alongside a 500-kcal daily energy deficit. Body weight fell by 8.82% on liraglutide and by 0.54% on placebo, a difference of 8.03 percentage points. Adverse events, mostly gastrointestinal, affected 80% on liraglutide and 57% on placebo, and there were no serious adverse events.

The trial is small, and 57 people completed follow-up, partly because COVID-19 restrictions disrupted final visits. Liraglutide is also the oldest and weakest of the drugs now used. Still, BARI-OPTIMISE is the strongest single piece of evidence that a GLP-1 medicine adds real weight loss after surgery, beyond what diet alone achieved in the placebo group.

Can a GLP-1 help when diabetes returns after surgery?

The GRAVITAS trial

Yes, for blood sugar. The GRAVITAS trial, by Miras and colleagues in Lancet Diabetes and Endocrinology in 2019, randomized 80 people whose type 2 diabetes persisted or returned at least 1 year after surgery, with HbA1c above 6.5%. They took liraglutide 1.8 mg daily or placebo in a 2:1 ratio for 26 weeks, alongside a reduced-calorie diet.

Liraglutide lowered HbA1c by 1.22 percentage points (13.3 mmol/mol) more than placebo, and the type of surgery made no significant difference. Adverse effects were reported by 45% on liraglutide and 41% on placebo, mainly gastrointestinal. GRAVITAS used the diabetes dose of liraglutide rather than the 3.0 mg weight-management dose, which makes it one of the few post-surgery trials of a lower dose, though its main outcome was glucose rather than weight. Our article on GLP-1 medicines and prediabetes covers the blood sugar picture in people who never had surgery.

Is semaglutide or tirzepatide better after a sleeve or bypass?

What the meta-analyses show

Tirzepatide has produced the largest average losses after surgery, followed by semaglutide, then liraglutide. A 2025 meta-analysis in Obesity Surgery pooled 19 studies with 1290 patients who had a suboptimal response or regain. After at least 3 months of treatment, pooled total weight loss was 9.24% on liraglutide, 11.38% on semaglutide and 15.50% on tirzepatide, or 8.56 kg, 11.62 kg and 12.60 kg.

Other reviews point the same way. Osorio Manyari and colleagues, also in Obesity Surgery in 2025, pooled 8 retrospective studies and 964 patients and found total weight loss of 10.97% on semaglutide and 13.63% on tirzepatide. Santos-Pereira and colleagues, in Frontiers in Endocrinology in 2026, found a 4.23% mean difference in favor of tirzepatide over semaglutide at 6 months. Golzarand and colleagues, in the International Journal of Obesity in 2025, reviewed 26 studies and found an overall 9.94% loss with GLP-1 medicines against 4.50% with non-GLP-1 obesity drugs.

The caveat is that almost all of this is retrospective clinic data. No randomized head-to-head trial has compared semaglutide and tirzepatide after surgery, and the Santos-Pereira authors flagged substantial heterogeneity across studies. The ranking is plausible and consistent with trials in non-surgical patients, which our semaglutide vs tirzepatide comparison covers, but it is not proven in this group.

How long does it take a GLP-1 to work after surgery?

Weight loss by treatment duration

Most of the loss arrives in the first 6 months, and it keeps building more slowly after that. In the same 2025 meta-analysis, liraglutide users lost 7.65% at 6 months or less, 10.22% between 6 and 12 months and 10.80% at 12 months or more. Semaglutide users lost 10.18% at 6 months and 13.15% at 12 months.

A 2026 study from Madrid suggests the effect can hold. Mera-Carreiro and colleagues followed 98 patients who regained at least 10% after gastric bypass. Those on liraglutide 3.0 mg kept a total weight loss of 14.84% at 12 months and 15.59% at 24 months. Those treated instead with endoscopic argon plasma coagulation, a procedure that narrows the connection between stomach pouch and intestine, were at 9.72% and 7.03%. At 24 months, 43% of the liraglutide group and 17% of the endoscopy group had a BMI under 30. Since these were patients who stayed on treatment, the long-term figures say little about what happens after stopping, a question our article on GLP-1 maintenance dosing takes up.

Is a GLP-1 a substitute for revision surgery?

Conversion to bypass versus medication

Not if the goal is the largest possible weight loss. Brown and colleagues, in Surgical Endoscopy in 2025, compared 4901 patients at NYU and partner centres who had a sleeve gastrectomy and then either converted to gastric bypass (3004) or started semaglutide or tirzepatide (1897). At 3 years, total weight loss was 26.1% after conversion and 13.7% on a GLP-1. After adjusting for sex, age, baseline BMI and race, conversion was associated with 11% greater weight loss. HbA1c control did not differ between the groups.

A similar gap shows up when the drug is used instead of surgery in the first place. In a matched cohort from the University of Illinois Chicago, published in Clinical Obesity in 2026, sleeve gastrectomy produced 30% total weight loss at 12 months against 12% on tirzepatide. Neither study was randomized, and patients who choose surgery may differ from those who choose a drug. A GLP-1 is a non-surgical option with a smaller expected effect, and for many people that trade is worth it.

Should a GLP-1 be started soon after surgery?

Early adjuvant use

The current evidence does not show a clear benefit from adding a GLP-1 in the first postoperative year. A 2026 exploratory analysis from Rush University Medical Center, published in the Journal of Surgical Research, looked at 808 patients. Those who started semaglutide or tirzepatide at a mean of 7.8 months after surgery did not lose significantly more weight at any time point than matched patients who did not.

In the sleeve group the GLP-1 users were numerically ahead, 22.6% against 18.3% total weight loss, but the P value was 0.07, and only 22 sleeve and 7 bypass patients received the drug. The authors called for larger prospective studies. For now, the strongest data apply to people at least a year out with regain or a weak response, which is how BARI-OPTIMISE, GRAVITAS and most meta-analyses defined their populations.

Are GLP-1 side effects different after bariatric surgery?

Common effects and rare serious ones

The common side effects look much like those in people who never had surgery. The 2025 Obesity Surgery meta-analysis reported nausea in 23%, vomiting in 6% and abdominal bloating in 2%, and 3% stopped treatment because of side effects. The 2026 Frontiers review likewise found no serious adverse events, with mostly mild gastrointestinal symptoms.

The rare problems are where a rearranged gut matters. A 2026 case report in ACG Case Reports Journal described life-threatening malnutrition and liver injury after semaglutide was started in a patient with a previous gastric bypass, which ended in intensive care, intravenous nutrition and an endoscopic reversal of the bypass. The authors described a dual-hit risk: a small, bypassed stomach plus a drug that further reduces intake.

Another 2026 case report, by Green and Glynn, described a 51-year-old woman without diabetes, 2 years after sleeve gastrectomy, who developed euglycaemic ketoacidosis after rapid dose escalation of tirzepatide. Her blood pH was 7.01 and her ketones 6 mmol/L with normal glucose. Single cases cannot give a rate, but both point at the same issue: people after surgery already eat small volumes, so anything that suppresses intake further needs close attention to protein, fluids and micronutrients. Our guide to micronutrient status on a GLP-1 protocol goes through the labs worth watching.

Does a microdose GLP-1 work after bariatric surgery?

What can and cannot be said

Nobody knows, because no study has tested microdose or below-label regimens in post-surgery patients. BARI-OPTIMISE used liraglutide 3.0 mg, and the meta-analyses pooled clinics using standard prescribing. The closest thing to lower-dose data is GRAVITAS, which used liraglutide 1.8 mg, and its main outcome was HbA1c rather than weight.

There is a reasonable argument for caution with dosing in this group. Post-surgery patients already have smaller stomachs, faster or altered transit, and a higher baseline risk of nutrient shortfalls. The ketoacidosis case followed rapid dose escalation. A slower climb, of the kind described in our article on the gentle ramp, is a sensible thing to raise with a bariatric team. Whether a lower dose keeps enough of the weight effect after surgery is an open question with no data behind either answer.

The practical points hold at any dose. Decisions belong with the surgical or obesity medicine team, who know the anatomy and the lab history. Protein, fluids and supplements prescribed after surgery matter more, not less, once appetite drops further. And because a GLP-1 slows how the stomach empties, the timing of other medicines and the guidance in our piece on gastric emptying and medication absorption apply here too.

Frequently Asked Questions